References
[1] P. Rawla. “Epidemiology of Prostate Cancer”. World Journal of Oncology. Vol. 10(2), pp. 63-89, 2019.
[2] T. Saika, N. Miura, T. Fukumoto, Y. Yanagihara, Y. Miyauchi, T. Kikugawa. “Role of robot‐assisted radical prostatectomy in locally advanced prostate cancer”. International Journal of Urology, Vol. 25(1), pp.30-35, 2018.
[3] F. Bray, J. Ferlay, I. Soerjomataram, RL. Siegel, LA. Torre, A. Jemal. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: a cancer journal for clinicians, vol: 68(6), pp. 394-424, 2018.
[4] RL Siegel, KD Miller, A. Jemal. “Cancer statistics, 2019”. CA: a cancer journal for clinicians, vol: 69(1), pp. 7-34, 2019.
[5] OP. Singh, V. Yogi, P. Redhu, HU Ghori, A. Pareek, N. Lal. “Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer”. Journal of cancer research and therapeutics, Vol.1;15(8), pp.39-41, 2019.
[6] A. Mathew, PS. George, KM JK, D. Vasudevan, FV. James. “Transition of cancer in populations in India”. Cancer epidemiology, Vol.1;58, pp.111-120, 2019.
[7] ME. Rezaee, CE. Ward, BD. Odom, M. Pollock. “Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012”. Preventive medicine. Vol.1;82, pp.73-76, 2016.
[8] SV. Carlsson, H. Lilja. “Perspective on Prostate Cancer Screening”. Clinical chemistry, Vol. 1;65(1) pp.24-27, 2019.
[9] S Harrison, K. Tilling, EL. Turner, JA Lane, A Simpkin, M. Davis, J. Donovan, FC. Hamdy, DE. Neal, RM Martin. “Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?”. Cancer Causes & Control, Vol. 1;27(12), pp.1465-1474, 2016.
[10] FM. Schumacher, AA Al Olama, SI. Berndt, S Benlloch, M Ahmed, EJ Saunders, T Dadaev, D Leongamornlert, E Anokian, C Cieza-Borrella, C. Goh. “Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci”. Nature genetics. Vol.50(7), pp.928, 2018.
[11] Al Olama AA, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, S Benlloch, DJ Hazelett, Z Wang, E Saunders, D. Leongamornlert. “A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer”. Nature genetics, Vol.46(10), pp.1103, 2014.
[12] NN Wang, Xu Y, K Yang, D Wei, YG Zhang, M Liu, XH Shi, SY Liang, L Sun, XQ Zhu, YG Yang. “Susceptibility loci associations with prostate cancer risk in northern Chinese men”. Asian Pacific Journal of Cancer Prevention, Vol.14(5), pp.3075-3078, 2013.
[13] Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, R Szulkin, M Annala, J Yan, LA Egevad. “A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding”. Nature genetics, Vol.46(2), pp.126, 2014.
[14] IG Mills. “HOXB13, RFX6 and prostate cancer risk”. Nature genetics, Vol.46(2), pp.94, 2014.
[15] S Jung, H Jin, RV Davuluri. “Identification of candidate regulatory SNPs by integrative analysis for prostate cancer genome data”. In Proceedings of the 6th ACM Conference on Bioinformatics, Computational Biology and Health Informatics pp. 278-285, 2015.
[16] Li XH, Xu Y, K Yang, JJ Shi, X Zhang, F Yang, H Yuan, X Zhu, YH Zhang, JY Wang, Z Yang. “Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men”. Journal of BU ON.: official journal of the Balkan Union of Oncology. Vol.20(5), pp.1223-1228, 2015.
[17] S. Poornima, K Subramanyam, IA Khan, Q Hasan. “The insertion and deletion (I28005D) polymorphism of the angiotensin I converting enzyme gene is a risk factor for osteoarthritis in an Asian Indian population”. Journal of the Renin-Angiotensin-Aldosterone System, Vol.16(4):1281-1287, 2015.
[18] M Darooei, F Khan, M Rehan, S. Zubeda, E Jeyashanker, S Annapurna, A Shah, S Maddali, Q Hasan. “MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women”. Journal of cellular biochemistry, Vol.120(1), pp.182-191, 2019.
[19] IA Khan, S Poornima, P Jahan, P Rao, Q Hasan. “Type 2 diabetes mellitus and the association of candidate genes in Asian Indian population from Hyderabad, India”. Journal of clinical and diagnostic research, Vol (11), pp. GC01-05, 2015.
[20] S. Daram, Z. Syeda, S. Poornima, S. Boppana, S. Prabhala, A. Sandhya, D. Ramakrishna, Q Hasan. “Association of androgen receptor (AR) CAG repeats and cytochrome P450 3a5*3 (cyp3a5*3) gene polymorphisms in men with prostate cancer from south India”. Journal of clinical and diagnostic research, 2019. (Accepted on 1st June 2019).
[21] P Korti, S Prabhala, E Jayashankar, AK Deshpande. “Study of transrectal ultrasound guided biopsies of prostate in correlation with serum prostate specific antigen level”. Indian Journal of Pathology and Oncology, vol: 4(4), pp. 604-610, 2017.
[22] S Lindström, FR Schumacher, D Campa, Albanes, G Andriole, SI Berndt, HB Bueno-de- Mesquita, SJ Chanock, WR Diver, JM Ganziano, SM Gapstur. “Replication of five prostate cancer loci identified in an Asian population results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)”. Cancer Epidemiology and Prevention Biomarkers, vol: 21(1), pp. 212-216, 2012.
[23] M Wang, F Liu, AW Hsing, X Wang, Q Shao, Qi J, Y Ye, Z Wang, H Chen, X Gao, G Wang. “Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case–control study in the ChinaPCa consortium”. Carcinogenesis, Vol.23;33(2), pp.356-360, 2011.
[24] R Takata, S Akamatsu, M Kubo, A Takahashi, N Hosono, T Kawaguchi, T Tsunoda, J Inazawa, N Kamatani, O Ogawa , T Fujioka. “Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population”. Nature genetics, Vol.42(9), pp.751, 2010.
[25] R Eeles, C Goh, E Castro, E Bancroft, M Guy, AA Olama Al, D Easton, Z Kote-Jarai. “The genetic epidemiology of prostate cancer and its clinical implications”. Nature reviews Urology, Vol.11(1), pp.18, 2014.
[26] S Aftab, L Semenec, JS Chu, N Chen. “Identification and characterization of novel human tissue-specific RFX transcription factors. BMC evolutionary biology”, Vol.8(1), pp.226-237, 2008.
[27] S Bhatlekar, JZ Fields, BM Boman. “HOX genes and their role in the development of human cancers. Journal of molecular medicine”, Vol.1;92(8), pp.811-823, 2014.
[28] D Sugiaman-Trapman, M Vitezic, EM Jouhilahti, A Mathelier, G Lauter, S Misra, CO Daub, J Kere, P Swoboda. “Characterization of the human RFX transcription factor family by regulatory and target gene analysis”. BMC genomics, Vol.19(1), pp.181-196, 2018.
[29] QZ Long, YF Du, XY Ding, X Li, WB Song ,Y Yang, P Zhang, JP Zhou, XG Liu. “Replication and fine mapping for association of the C2orf43, FOXP4, GPRC6A and RFX6 genes with prostate cancer in the Chinese population”. PLoS One, Vol.7(5), e37866, pp. 1-6, 2012.